DOP2005000229A - PIRAZOLO [3,4-B] PIRIDINES AND THERAPEUTIC INDAZOLS - Google Patents

PIRAZOLO [3,4-B] PIRIDINES AND THERAPEUTIC INDAZOLS

Info

Publication number
DOP2005000229A
DOP2005000229A DO2005000229A DO2005000229A DOP2005000229A DO P2005000229 A DOP2005000229 A DO P2005000229A DO 2005000229 A DO2005000229 A DO 2005000229A DO 2005000229 A DO2005000229 A DO 2005000229A DO P2005000229 A DOP2005000229 A DO P2005000229A
Authority
DO
Dominican Republic
Prior art keywords
indazols
piridines
pirazolo
therapeutic
formula
Prior art date
Application number
DO2005000229A
Other languages
Spanish (es)
Inventor
Robert M Schelkun
Po-Wai Yuen
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Priority to DO2005000229A priority Critical patent/DOP2005000229A/en
Publication of DOP2005000229A publication Critical patent/DOP2005000229A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona compuestos de la formula I: en los que R2, R3, R4, R5, R6, R7, X, y L tienen cualquiera de los valores definidos en la memoria descriptiva, y sales farmaceuticamente aceptables de los mismos, que son utiles como agentes en el tratamiento de trastomos y enfermedades del sistema nervioso central incluyendo el trastorno de deficit de atención con hiperactividad, dolor neuropatico, incontinencia urinaria, ansiedad, depresion, y esquizofrenia y fibromialgia. Tambien se proporcionan composiciones farmaceuticas que comprenden uno o mas compuestos de la formula I.The present invention provides compounds of the formula I: wherein R2, R3, R4, R5, R6, R7, X, and L have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, which are Useful as agents in the treatment of disorders and diseases of the central nervous system including attention deficit disorder with hyperactivity, neuropathic pain, urinary incontinence, anxiety, depression, and schizophrenia and fibromyalgia. Pharmaceutical compositions comprising one or more compounds of the formula I are also provided.

DO2005000229A 2005-11-10 2005-11-10 PIRAZOLO [3,4-B] PIRIDINES AND THERAPEUTIC INDAZOLS DOP2005000229A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DO2005000229A DOP2005000229A (en) 2005-11-10 2005-11-10 PIRAZOLO [3,4-B] PIRIDINES AND THERAPEUTIC INDAZOLS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DO2005000229A DOP2005000229A (en) 2005-11-10 2005-11-10 PIRAZOLO [3,4-B] PIRIDINES AND THERAPEUTIC INDAZOLS

Publications (1)

Publication Number Publication Date
DOP2005000229A true DOP2005000229A (en) 2006-05-31

Family

ID=44340210

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2005000229A DOP2005000229A (en) 2005-11-10 2005-11-10 PIRAZOLO [3,4-B] PIRIDINES AND THERAPEUTIC INDAZOLS

Country Status (1)

Country Link
DO (1) DOP2005000229A (en)

Similar Documents

Publication Publication Date Title
CR9155A (en) PIRAZOLO (3,4-b) PIRIDINES AND THERAPEUTIC INDAZOLS
UY30641A1 (en) DERIVATIVES OF 2- [1H-PIRAZOL-5-IL] AND 2- [2H-PIRAZOL-3-IL] HAVE [3,2-C] REPLACED PYRIDINS, THEIR PHARMACEUTICALLY ACCEPTABLE SALTS AND APPLICATIONS
UY28873A1 (en) NEW MORFINA COMPOUNDS COMPOSITIONS AND PREPARATION PROCEDURES
NI200900204A (en) AMINO-HETEROCYCLIC COMPOUNDS. Case: PC 33468A
CL2009000975A1 (en) Compounds derived from quinuclidine, acetylcholine a7 receptor ligands; its pharmaceutical composition; its use for the treatment of disorders of the central nervous system, especially affective and neurodegenerative diseases such as schizophrenia and Alzheimer's.
ECSP088863A (en) COMPOUNDS THAT ARE AGONISTS OF MUSCARINIC RECEPTORS AND THAT MAY BE EFFECTIVE IN THE TREATMENT OF PAIN, ALZHEIMER'S DISEASE AND / OR SCHIZOPHRENIA
PA8627201A1 (en) IMIDAZOL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS
MA32898B1 (en) POSITIVE ALLOSTERIC MODULATORS OF ARYLMETHYLBENZOQUINAZOLINONE M1 RECEPTOR
CR20120389A (en) SUBSTITUTED COMPOUNDS OF N- (1H-INDAZOL-4-IL) IMIDAZO [1,2-a] PIRIDIN-3-CARBOXAMIDE AS CFMS INHIBITORS
WO2007038209A3 (en) Fused tetracyclic mglur1 antagonists as therapeutic agents
TW200609231A (en) Mglur1 antagonists as therapeutic agents
CR10314A (en) COMPOUNDS THAT HAVE ACTIVITY IN THE RECEIVER M 1 AND ITS USES IN MEDICINE
ECSP055719A (en) TIAZOL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS
UY31346A1 (en) COMPOUNDS THAT HAVE ACTIVITY IN THE RECEIVER M1 AND ITS USES IN MEDICINE
ECSP088967A (en) MUSCARINIC RECEIVER AGONISTS THAT ARE EFFECTIVE IN THE TREATMENT OF PAIN, ALZHEIMER'S DISEASE AND SCHIZOPHRENIA
DE602006019911D1 (en) MGLUR1 ANTAGONISTS AS THERAPEUTIC ACTIVITIES
UY30377A1 (en) FUSIONATED TRICYCLE INHIBITORS OF SULFONAMIDE OF GAMA-SECRETASA
ECSP088966A (en) MUSCARINIC RECEIVER AGONISTS THAT ARE EFFECTIVE IN THE TREATMENT OF PAIN, ALZHEIMER'S DISEASE AND SCHIZOPHRENIA
CY1108942T1 (en) 2- (1H-indolylsulfanyl) -Arylamine derivative for use in the treatment of affective disorders, pain, ADHD and anxiety of urinary incontinence
MX2008002366A (en) FUSED TRICYCLIC mGluR1 ANTAGONISTS AS THERAPEUTIC AGENTS.
UY30029A1 (en) DERIVATIVES OF PIPERIDINE, ITS PHARMACEUTICALLY ACCEPTABLE SALTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND APPLICATIONS
TW200740826A (en) Fused tricyclic mGluR1 antagonists as therapeutic agents
ATE552257T1 (en) POSITIVE ALLOSTERIC QUINOLICIDINONE M1 RECEPTOR MODULATORS
PA8720601A1 (en) NEW THERAPEUTIC COMBINATIONS FOR THE TREATMENT OR PREVENTION OF PSYCHOTIC DISORDERS
BRPI0817433A2 (en) Piperidinyl and piperazinyl gamma secretase modulators